peptide or protein carboxyl-terminal blocking

The elongation of a fatty acid chain by the sequential addition of two-carbon units.

The modification of a protein by amino acid glucuronidation.

Any process that initiates the activity of the inactive enzyme adenylate cyclase.

dopamine receptor, adenylate cyclase activating pathway

dopamine receptor, adenylyl cyclase activating pathway

The series of molecular signals generated as a consequence of a dopamine receptor binding to its physiological ligand, followed by activation of adenylyl cyclase and a subsequent increase in the concentration of cyclic AMP.

serotonin receptor, adenylate cyclase activating pathway

serotonin receptor, adenylyl cyclase activating pathway

The series of molecular signals generated as a consequence of a serotonin receptor binding to its physiological ligand, followed by activation of adenylyl cyclase and a subsequent increase in the concentration of cyclic AMP.

G-protein signaling, adenylate cyclase inhibiting pathway

G-protein signalling, adenylyl cyclase inhibiting pathway

The series of molecular signals generated as a consequence of a G-protein coupled receptor binding to its physiological ligand, followed by inhibition of adenylyl cyclase and a subsequent decrease in the concentration of cyclic AMP.

negative regulation of adenylate cyclase activity

negative regulation of adenylyl cyclase activity

Any process that stops, prevents or reduces the rate, frequency or extent of adenylate cyclase activity.

dopamine receptor, adenylate cyclase inhibiting pathway

dopamine receptor, adenylyl cyclase inhibiting pathway

The series of molecular signals generated as a consequence of a dopamine receptor binding to its physiological ligand, followed by inhibition of adenylyl cyclase and a subsequent decrease in the concentration of cyclic AMP.

metabotropic glutamate receptor, adenylate cyclase inhibiting pathway

metabotropic glutamate receptor, adenylyl cyclase inhibiting pathway

The series of molecular signals generated as a consequence of a metabotropic glutamate receptor binding to its physiological ligand, followed by inhibition of adenylyl cyclase and a subsequent decrease in the concentration of cyclic AMP.